

IMPACT-AD Informational Webinar

December 15, 2020

Rema Raman, University of Southern California
Josh Grill, University of California, Irvine

IMPACT-AD

Institute on Methods and Protocols for Advancement of Clinical
Trials in ADRD



ADRD Trials

- Key to the US National Plan to Address ADRD will be clinical trials of therapies that can slow or prevent the onset of symptoms
- Critical need to increase the pipeline of qualified investigators to design and conduct clinical trials in ADRD
- Equally critical is for the makeup of this pool of investigators to be diversified
- ADRD study designs are complex, multidisciplinary, and unique





IMPACT-AD

Institute on Methods and Protocols for
Advancement of Clinical Trials in ADRD

- A comprehensive, interactive, modern training course intended to provide the necessary skills and training for promising investigators to take their careers in ADRD trials to the next level
- Leverage the collective expertise of the NIA-funded Alzheimer's Clinical Trial Consortium (ACTC)

Acknowledgements



- Neelum T. Aggarwal (Rush University)
- Paul Aisen (University of Southern California)
- Laura Baker (Wake Forest University)
- Karen Bell (Columbia University)
- Jeffrey Burns (Kansas University)
- Jeff Cummings (Cleveland Clinic Lou Ruvo Center/UNLV)
- Maria Carrillo (Alzheimer's Association)
- Michael Donohue (University of Southern California)
- Hiroko Dodge (Oregon Health & Sciences University)
- Mark Espeland (Wake Forest University)
- Keith Fargo (Alzheimer's Association)
- Holly Lynch Fernandez (University of Pennsylvania)
- Howard Fillit (Alzheimer's Drug Discovery Foundation)
- Daniel Gillen (University of California, Irvine)
- David Geldmacher (University of Alabama at Birmingham)
- Judith Heidebrink (University of Michigan)
- Carl V. Hill (Alzheimer's Association)
- Gregory Jicha (University of Kentucky)
- Gustavo Jimenez-Maggiora (University of Southern California)
- Jason Karlawish (University of Pennsylvania)
- David Knopman (Mayo Clinic)
- Kristina McLinden (National Institute on Aging)
- Bri McWhorter (Activate to Captivate)
- Abigail O'Connell (Wake Forest University)
- John Olichney (University of California, Davis)
- Ronald Petersen (Mayo Clinic)
- Jeremy Pizzola (University of Southern California)
- Michael Rafii (University of Southern California)
- Dorene Rentz (Brigham and Women's Hospital, Harvard University)
- Robert Rissman (University of Southern California, University of California, San Diego)
- Laurie Ryan (National Institute on Aging)
- Stephen Salloway (Butler Hospital, Brown University)
- Mary Sano (Mount Sinai)
- Gopalan Sethuraman (University of Southern California)
- Amanda Smith (University of Southern Florida)
- Heather Snyder (Alzheimer's Association)
- Reisa Sperling (Brigham and Women's Hospital, Harvard University)
- David Sultzer (University of California, Irvine)
- Christopher Van Dyck (Yale University)
- Christopher Weber (Alzheimer's Association)

IMPACT-AD is supported by National Institute on Aging (NIA) grant number U13AG067696, Alzheimer's Clinical Trials Consortium (ACTC) NIA grant number U24AG057437 and the Alzheimer's Association grant number SG-20-693744.

Course Objectives

- position trainees to secure IRB approval, funding, or other necessary milestones toward performance of a clinical trial;
- facilitate career choices toward ADRD research for investigators; and
- increase the pipeline of qualified investigators of diverse professional and demographic backgrounds for the future of ADRD research.

IMPACT-AD has 2 Tracks

- Professional Track
 - Any clinical trials professional
 - 2.5 days
 - N=20
- Fellowship Track
 - Future Clinical Trials Investigators
 - 4.5 days
 - Small group mentorship on protocol development
 - 3 trainees; 3 mentors (2 clinical, 1 biostatistics)
 - N=15

IMPACT-AD Curriculum Sessions

Didactics


1. AD trial designs
2. Participant-related issues
3. Trial ethics
4. Design and analysis: Nuts and bolts
5. Design choices
6. Populations, indications, and outcomes
7. Statistical considerations
8. Study management: Serving as PI
9. Securing funding

1-4, both tracks; 5-9 Fellowship track only


Protocol Development (Fellowship Track)

1. Design choices
2. Populations, indications, and outcomes
3. Statistical considerations
4. Study management: Serving as PI
5. Securing funding

2020 IMPACT-AD



- Virtual format
- Reduced days/length of days
- Maintained curriculum content, including active learning workshops
 - Diversity and inclusion
 - Publications
 - Scientific communication
 - Protocol development



2020 Feedback



“IMPACT-AD has exceeded expectations!! Thank you for all the effort you’ve put into and sense of community you have created through this course.”



“I thought the first IMPACT-AD was a phenomenal success all the way through planning, virtual pivot and production.”



“It was such a pleasure to have the opportunity to learn from all of the faculty and trainees. This program was amazing”



“This was a fantastic course! Very inspiring speakers and loved every minute of it”

2021 Applications

RFA Outreach

Alzheimer's Association's International Society to Advance Alzheimer's Research and Treatment (ISTAART) mailing list

National Institute on Aging's (NIA) mailing list to FY 2019 grantees

National Alzheimer's Coordinating Center's mailing list

Alzheimer's Association's active research awardees list

ACTC steering committee members and investigative teams for numerous studies coordinated by ATRI

Application Components

Career Statement

Letter of Support

NIH Biosketch

Protocol Synopsis
(Fellowship Track only)

Other Key Learnings

- Applicants may apply to only one track
- Letters of support matter
 - Only letter per track for a PI/mentor
 - Letters should align with the IMPACT-AD goals and objectives
- Fellowship track applicants should propose a trial (see NIH definition)
 - Non-pharmacological trials outnumbered drug trials
 - Observational and cohort studies not as well received
- Diversity means many things
 - Professional background, expertise, demographics, geography

Key Dates

- RFA dissemination January 2021
- Application portal opens January 2021
- Application portal closes March 2021
- Application review committees meet April 2021
- Decision notifications May 2021
- IMPACT-AD 2021 September 2021

IMPACT-AD

Institute on Methods
and Protocols for
Advancement of
Clinical Trials in
ADRD

A comprehensive training



▶ Watch a message from Richard J. Hodes, MD,
Director of the National Institute on Aging

<https://impact-ad.org>

See you in 2021!

